Owiglit-PG2 Tablet is a combination oral hypoglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of its active ingredients to achieve optimal glycemic control. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Owiglit-PG2 is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with hepatic, renal, or cardiac impairment, and regular monitoring of blood glucose, liver function, and hematologic parameters is recommended. This combination therapy should be used under medical supervision to minimize adverse effects and optimize therapeutic outcomes.